Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Who Took Part

The abstract describes 2 men taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Measurements were made by echocardiographic Doppler that examined 3 systolic time intervals, as follows: QS(2) (time from Q wave on electrocardiogram to the closure of the aortic valve), left ventricular ejection time, and pre-ejection period, all corrected for changes in heart rate.

Serial systolic time interval and heart rate measurements were obtained on days 1, 15, and 16.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the men and researchers unaware of who received Teriparatide.

Some men received a placebo instead of Teriparatide, giving a reference point.

Each person switched between Teriparatide and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Calcium Channels, Cardiotonic Agents, Digoxin, Heart Rate and Teriparatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide in 2 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Teriparatide compound page, all human trials.